Category Archives: Cancer Stem Cell

Cancer Stem Cell News is an online publication and email newsletter that curates the top research publications and reviews about cancer progenitor cells and cancer stem cells.
Subscribe
Cancer Stem Cell News consolidates the most recent publications covering research areas such as the identification and isolation of cancer stem cells, their proliferation and differentiation characteristics, gene expression and regulatory pathways, and the development of anti-cancer therapies. We also include cancer stem cell jobs and events hosted by leading research organizations, societies, and institutes.

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage II of Phase II Clinical Trial in Acute Myeloid Leukemia

Bio-Path Holdings, Inc. announced the successful completion of the safety run-in of the Stage II of the Phase II clinical study of prexigebersen, a liposomal Grb2 antisense, for the treatment of acute myeloid leukemia (AML), in combination with frontline therapies, decitabine and venetoclax, in AML patients.
[Bio-Path Holdings, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

C3G Downregulation Induces the Acquisition of a Mesenchymal Phenotype That Enhances Aggressiveness of Glioblastoma Cells

The authors report that C3G downregulation promoted the acquisition of a more mesenchymal phenotype that enhanced the migratory and invasive capacity of glioblastoma cells.
[Cell Death & Disease]
Manzano, S., Gutierrez-Uzquiza, A., Bragado, P., Sequera, C., Herranz, Ó., Rodrigo-Faus, M., Jauregui, P., Morgner, S., Rubio, I., Guerrero, C., & Porras, A. (2021). C3G downregulation induces the acquisition of a mesenchymal phenotype that enhances aggressiveness of glioblastoma cells. Cell Death & Disease, 12(4), 1–17. https://doi.org/10.1038/s41419-021-03631-w Cite
Full Article
Bookmark

No account yet? Register

0
Share

miR-146 Connects Stem Cell Identity with Metabolism and Pharmacological Resistance in Breast Cancer

Scientists showed that miR-146 was relevant for normal mammary stem cell and mammary cancer stem cell activity.
[Journal of Cell Biology]
Tordonato, C., Marzi, M. J., Giangreco, G., Freddi, S., Bonetti, P., Tosoni, D., Di Fiore, P. P., & Nicassio, F. (2021). miR-146 connects stem cell identity with metabolism and pharmacological resistance in breast cancer. Journal of Cell Biology, 220(e202009053). https://doi.org/10.1083/jcb.202009053 Cite
Full Article
Bookmark

No account yet? Register

0
Share

The AXL-PYK2-PKCα Axis as a Nexus of Stemness Circuits in TNBC

Researchers identified a clinically relevant signaling nexus mediated by AXL receptor, PYK2 and PKCα and show its impact on stemness in triple-negative breast cancer.
[Life Science Alliance]
Khera, L., Vinik, Y., Maina, F., & Lev, S. (2021). The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC. Life Science Alliance, 4(6). https://doi.org/10.26508/lsa.202000985 Cite
Full Article
Bookmark

No account yet? Register

0
Share

Long Noncoding RNA McF2l-AS1 Promotes the Cancer Stem Cell-Like Traits in Non-Small Cell Lung Cancer Cells through Regulating miR-873-5p Level

Functional experiments showed that MCF2L‐AS1 knockdown suppressed the cancer stem cell‐like traits of non-small cell lung cancer cells through qRT‐PCR, western blot, tumor‐sphere formation, and ALDH activity detection.
[Environmental Toxicology]
Li, S., & Lin, L. (n.d.). Long noncoding RNA MCF2L-AS1 promotes the cancer stem cell-like traits in non-small cell lung cancer cells through regulating miR-873-5p level. Environmental Toxicology, n/a(n/a). https://doi.org/https://doi.org/10.1002/tox.23142 Cite
Abstract
Bookmark

No account yet? Register

0
Share

Anticancer Effects of Non-Steroidal Anti-Inflammatory Drugs against Cancer Cells and Cancer Stem Cells

Investigators identified non-steroidal anti-inflammatory drugs (NSAIDs) that enhanced the anticancer effect of cisplatin; the effects of 17 NSAIDs in lung cancer cells and their spheroids as CSCs were evaluated.
[Toxicology in Vitro]
Okamoto, K., Saito, Y., Narumi, K., Furugen, A., Iseki, K., & Kobayashi, M. (2021). Anticancer effects of non-steroidal anti-inflammatory drugs against cancer cells and cancer stem cells. Toxicology in Vitro, 105155. https://doi.org/10.1016/j.tiv.2021.105155 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

Role of Glioblastoma Stem Cells in Cancer Therapeutic Resistance: A Perspective on Antineoplastic Agents from Natural Sources and Chemical Derivatives

Scientists describe major intrinsic and extrinsic mechanisms that mediate chemoradioresistant glioblastoma stem cells and therapies based on antineoplastic agents from natural sources, derivatives, and synthetics used alone or in synergistic combination with conventional treatment.
[Current Stem Cell Research & Therapy]
Alves, A. L. V., Gomes, I. N. F., Carloni, A. C., Rosa, M. N., da Silva, L. S., Evangelista, A. F., Reis, R. M., & Silva, V. A. O. (2021). Role of glioblastoma stem cells in cancer therapeutic resistance: a perspective on antineoplastic agents from natural sources and chemical derivatives. Stem Cell Research & Therapy, 12(1), 206. https://doi.org/10.1186/s13287-021-02231-x Cite
Full Article
Bookmark

No account yet? Register

0
Share

Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase III Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML)

Rafael Pharmaceuticals, Inc. announced that it has crossed the enrollment of 150 patients in its Phase III clinical trial for patients with relapsed or refractory AML.
[Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)]
Press Release
Bookmark

No account yet? Register

0
Share

WPD Pharmaceuticals Announces Amended Sublicense Agreement with Moleculin Biotech for WP1066, WP1122 and Annamycin Drug Candidates

WPD Pharmaceuticals Inc. announced that is has entered into an amended and restated sublicense agreement with Moleculin Biotech, Inc.
[WPD Pharmaceuticals, Inc.]
Press Release
Bookmark

No account yet? Register

0
Share

FOSL1 Promotes Metastasis of Head and Neck Squamous Cell Carcinoma through Super-Enhancer-Driven Transcription Program

The authors demonstrated that FOSL1 served as the dominate AP1 family member and was significantly upregulated in head and neck squamous cell carcinoma (HNSCC) tumor tissues and correlated with metastasis of HNSCC.
[Molecular Therapy]
Zhang, M., Hoyle, R. G., Ma, Z., Sun, B., Cai, W., Cai, H., Xie, N., Zhang, Y., Hou, J., Liu, X., Chen, D., Kellogg, G. E., Harada, H., Sun, Y., Wang, C., & Li, J. (2021). FOSL1 Promotes Metastasis of Head and Neck Squamous Cell Carcinoma Through Super-Enhancer-Driven Transcription Program. Molecular Therapy, 0(0). https://doi.org/10.1016/j.ymthe.2021.03.024 Cite
AbstractGraphical Abstract
Bookmark

No account yet? Register

0
Share

HOXBLINC Long Non-Coding RNA Activation Promotes Leukemogenesis in NPM1-Mutant Acute Myeloid Leukemia

Scientists showed that the activation of HOXBLINC, a HOXB locus-associated long non-coding RNA, was a critical downstream mediator of NPM1c+-associated leukemic transcription program and leukemogenesis.
[Nature Communications]
Zhu, G., Luo, H., Feng, Y., Guryanova, O. A., Xu, J., Chen, S., Lai, Q., Sharma, A., Xu, B., Zhao, Z., Feng, R., Ni, H., Claxton, D., Guo, Y., Mesa, R. A., Qiu, Y., Yang, F.-C., Li, W., Nimer, S. D., … Xu, M. (2021). HOXBLINC long non-coding RNA activation promotes leukemogenesis in NPM1-mutant acute myeloid leukemia. Nature Communications, 12(1), 1956. https://doi.org/10.1038/s41467-021-22095-2 Cite
Full Article
Bookmark

No account yet? Register

0
Share
Share